Learn more from Dr. Michael Oxman, professor of medicine and pathology at the University of California, San Diego School of Medicine, and Dr. William Schaffner, professor and chair of preventive medicine at Vanderbilt University School of Medicine. Will this program also lower overall immunization costs? Dr. Mark Nolan Hill hosts.
Vaccinating for Adult Shingles: New Initiatives
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
A vaccine for adult Shingles was approved in 2006 by the FDA and is in use today. Yet delivery of this vaccination has not been as widespread as it could and should be. With this in mind, many hospitals and clinics are working to improve on their current approach to its distribution; at some health centers, this includes allowing pharmacists to administer the vaccine. Can this program be implemented nationwide, in accordance with local and state laws? Would this program necessitate any change in insurance coverage for providers?
Recommended
Details
Presenters
Overview
A vaccine for adult Shingles was approved in 2006 by the FDA and is in use today. Yet delivery of this vaccination has not been as widespread as it could and should be. With this in mind, many hospitals and clinics are working to improve on their current approach to its distribution; at some health centers, this includes allowing pharmacists to administer the vaccine. Can this program be implemented nationwide, in accordance with local and state laws? Would this program necessitate any change in insurance coverage for providers? Learn more from Dr. Michael Oxman, professor of medicine and pathology at the University of California, San Diego School of Medicine, and Dr. William Schaffner, professor and chair of preventive medicine at Vanderbilt University School of Medicine. Will this program also lower overall immunization costs? Dr. Mark Nolan Hill hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
0.50 credits
<p>IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base</p>
CME/CE
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
0.50 credits
<p>IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue</p>
CME/CE Broadcast Replay
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
1.00 credits
<p>Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
Cardiology
FINE-HEART Pooled Analysis
<p><span data-teams="true">FINE-HEART Pooled Analysis</span></p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?